RECCE PHARMACEUTICALS LTD - Announcements

0.00%

37.5¢

Market Cap $108.4M

Healthcare Biotechnology

An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce... An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of synthetic anti-infectives.More

Corporate Spotlight

An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of synthetic anti-infectives.
View the full Corporate Spotlight

Recce accelerates commercialisation

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

RCE	Pause in Trading	PRICE SENSITIVE	07/12/22	113.49KB	Share
RCE	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/10/22	581.3KB	Share
RCE	Anti-Infective Portfolio Update and Webinar details	PRICE SENSITIVE	19/10/22	3.36MB	Share
RCE	Pause in Trading	PRICE SENSITIVE	19/10/22	115.99KB	Share
RCE	R327 COVID Study Update	PRICE SENSITIVE	18/10/22	398.4KB	Share
RCE	Pause in trading	PRICE SENSITIVE	18/10/22	115.68KB	Share
RCE	Expansion and Acceleration of Clinical Programs	PRICE SENSITIVE	27/09/22	308.99KB	Share
RCE	Appendix 4E	PRICE SENSITIVE	31/08/22	244.24KB	Share
RCE	Phase I Clinical Trial of R327 I.V. - 6000mg Complete	PRICE SENSITIVE	22/08/22	313.84KB	Share
RCE	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	01/08/22	944.67KB	Share
RCE	Corporate Presentation - Aussie Equities Day 2022	PRICE SENSITIVE	28/07/22	2.22MB	Share
RCE	Phase I Positive Safety Data - 4000mg Complete	PRICE SENSITIVE	21/06/22	241.36KB	Share
RCE	Phase I Clinical Trial R327 Advances to 4000mg	PRICE SENSITIVE	20/05/22	241.06KB	Share
RCE	Corporate Presentation - Biotech Investor Lunch	PRICE SENSITIVE	16/05/22	2.48MB	Share
RCE	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	02/05/22	436.79KB	Share
RCE	Phase I Clinical Trial R327 Advances to High Dose Cohort	PRICE SENSITIVE	12/04/22	408.22KB	Share
RCE	Anti-Viral Patent Granted in Hong Kong	PRICE SENSITIVE	11/04/22	225.31KB	Share
RCE	Positive safety data from 4th Cohort -Phase I Clinical Trial	PRICE SENSITIVE	30/03/22	247.62KB	Share
RCE	$3.08m R&D Rebate Received	PRICE SENSITIVE	28/03/22	238.52KB	Share
RCE	Safety Committee Clears PhI R327 Dose Increase	PRICE SENSITIVE	07/03/22	265.52KB	Share
RCE	S&P DJI Announces March 2022 Quarterly Rebalance	PRICE SENSITIVE	04/03/22	175.5KB	Share
RCE	Appendix 4D and Interim Financial Report	PRICE SENSITIVE	28/02/22	265.76KB	Share
RCE	Positive Safety Continues in 3rd Cohort PhI Clinical Trial	PRICE SENSITIVE	21/02/22	266.79KB	Share
RCE	Positive Safety Data from Third Cohort of PI Clinical Trial	PRICE SENSITIVE	08/02/22	247.91KB	Share
RCE	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/22	441.2KB	Share
RCE	Positive Safety Data from Second Cohort of PI Clinical Trial	PRICE SENSITIVE	18/01/22	267.69KB	Share
RCE	Positive Safety Data from Phase 1 Clinical Trial	PRICE SENSITIVE	07/01/22	316.58KB	Share
RCE	Patients to be Dosed in Ph 1 IV Clinical Trial of R327	PRICE SENSITIVE	15/12/21	246.15KB	Share
RCE	Update on Phase I/II Clinical Trial for Burn Wound Infection	PRICE SENSITIVE	07/12/21	273.37KB	Share
RCE	Opening R&D Address at World AMR Congress	PRICE SENSITIVE	08/11/21	6.74MB	Share
RCE	Appendix 4C and Activity Report	PRICE SENSITIVE	29/10/21	413.29KB	Share
RCE	Ethics Approval to Start Phase 1 Intravenous Clinical Trial	PRICE SENSITIVE	25/10/21	247.07KB	Share
RCE	Reinstatement to Official Quotation	PRICE SENSITIVE	12/10/21	85.72KB	Share
RCE	Court Orders Granted	PRICE SENSITIVE	12/10/21	404.72KB	Share
RCE	Suspension from Official Quotation	PRICE SENSITIVE	12/10/21	240.35KB	Share
RCE	Trading halt	PRICE SENSITIVE	08/10/21	696.71KB	Share
RCE	Pause in Trading	PRICE SENSITIVE	08/10/21	116.55KB	Share
RCE	R327 Phase I Clinical Trial Registered on ANZCTR	PRICE SENSITIVE	30/09/21	288.3KB	Share
RCE	Appendix 4E	PRICE SENSITIVE	31/08/21	261.73KB	Share
RCE	Recce Receives Further Innovation Connections Grant	PRICE SENSITIVE	11/08/21	225.61KB	Share
RCE	Appendix 4C and Activity Report	PRICE SENSITIVE	30/07/21	433.45KB	Share
RCE	Anti-Viral Patent Granted in USA for RECCE Anti-Infectives	PRICE SENSITIVE	22/07/21	270.51KB	Share
RCE	Anti-Viral Patent Granted in China	PRICE SENSITIVE	20/07/21	270.49KB	Share
RCE	Outstanding Efficacy Against Flesh-Eating Bacteria	PRICE SENSITIVE	19/07/21	423.92KB	Share
RCE	Multiple Patients Dosed in Topical Phase I/II Clinical Trial	PRICE SENSITIVE	12/07/21	296.93KB	Share
RCE	Recce Clinical Pipeline Update	PRICE SENSITIVE	07/06/21	291.67KB	Share
RCE	R327 Demonstrates World First Multiple Mechanisms of Action	PRICE SENSITIVE	27/05/21	1.26MB	Share
RCE	R327 to Stage 2 of SARS-CoV-2 Antiviral Screening at CSIRO	PRICE SENSITIVE	19/05/21	328.14KB	Share
RCE	Positive Data on RECCE 327 Against All Six ESKAPE Pathogens	PRICE SENSITIVE	04/05/21	883.37KB	Share
RCE	Appendix 4C and Activity Report	PRICE SENSITIVE	27/04/21	453.68KB	Share
RCE	RECCE 327 Registered for Topical Burns Study in Humans	PRICE SENSITIVE	15/04/21	296.62KB	Share
RCE	Positive Sinusitis Patient Update - Special Access Scheme	PRICE SENSITIVE	07/04/21	300.36KB	Share
RCE	Positive Sinusitis Data Against Infection	PRICE SENSITIVE	01/04/21	618KB	Share
RCE	Anti-Viral Patent Granted in EU for RECCE Anti-Infectives	PRICE SENSITIVE	30/03/21	228.62KB	Share
RCE	S&P DJI Announces March 2021 Quarterly Rebalance	PRICE SENSITIVE	12/03/21	183.24KB	Share
RCE	Recce Pharmaceuticals Dual Lists on Frankfurt Stock Exchange	PRICE SENSITIVE	08/03/21	329.63KB	Share
RCE	Appendix 4D and Half Yearly Report	PRICE SENSITIVE	25/02/21	451.22KB	Share
RCE	Recce Applies for Dual Listing on Frankfurt Stock Exchange	PRICE SENSITIVE	24/02/21	325.24KB	Share
RCE	Fiona Stanley Hospital Phase I/II Clinical Trial Agreement	PRICE SENSITIVE	16/02/21	413.46KB	Share
RCE	Further Encouraging COVID Results at Doherty	PRICE SENSITIVE	12/02/21	409.16KB	Share
RCE	R&D Incentive Rebate Received	PRICE SENSITIVE	03/02/21	324.6KB	Share
RCE	Appendix 4C and Activity Report	PRICE SENSITIVE	28/01/21	531.85KB	Share
RCE	Positive Intranasal Animal Data against SARS-CoV-2 in Study	PRICE SENSITIVE	23/12/20	542.82KB	Share
RCE	RCE Awarded AusIndustry Advanced Overseas Anti-Viral Finding	PRICE SENSITIVE	08/12/20	370.39KB	Share
RCE	Recce Awarded AusIndustry Advanced Overseas (R&D) Finding	PRICE SENSITIVE	26/11/20	331.4KB	Share
RCE	Anti-Viral Patent Granted in Japan for RECCE Anti-Infectives	PRICE SENSITIVE	23/11/20	297.82KB	Share
RCE	Reinstatement to Official Quotation	PRICE SENSITIVE	10/11/20	400.35KB	Share
RCE	Encouraging Results Against SARS-CoV-2 Virus	PRICE SENSITIVE	10/11/20	454.28KB	Share
RCE	Suspension from Official Quotation	PRICE SENSITIVE	05/11/20	422.52KB	Share
RCE	Trading Halt	PRICE SENSITIVE	03/11/20	465.12KB	Share
RCE	Appendix 4C and Activity Report	PRICE SENSITIVE	21/10/20	797.75KB	Share
RCE	HREC Approval to Start Phase I/II Burns Wound Study	PRICE SENSITIVE	16/10/20	331.16KB	Share
RCE	Trading Halt	PRICE SENSITIVE	14/10/20	465.67KB	Share
RCE	Pause in trading	PRICE SENSITIVE	14/10/20	116.3KB	Share
RCE	R&D Incentive Rebate Received	PRICE SENSITIVE	05/10/20	316.17KB	Share
RCE	Murdoch Children's Research Institute, R435 Against H.Pylori	PRICE SENSITIVE	30/09/20	377.28KB	Share
RCE	Recce Completes Capital Raising of $27.95m	PRICE SENSITIVE	23/09/20	350.89KB	Share
RCE	Trading Halt	PRICE SENSITIVE	21/09/20	507.12KB	Share
RCE	R327 Phase I Study - Australia's CMAX Clinical Facility	PRICE SENSITIVE	10/09/20	377.7KB	Share
RCE	Positive & Concentration-Dependent Efficacy Against COVID-19	PRICE SENSITIVE	08/09/20	621.04KB	Share
RCE	Trading Halt	PRICE SENSITIVE	07/09/20	649.24KB	Share
RCE	Pause in Trading	PRICE SENSITIVE	07/09/20	116.3KB	Share
RCE	Recce Pharmaceuticals Receives Innovation Connections Grant	PRICE SENSITIVE	01/09/20	309.07KB	Share
RCE	Appendix 4E	PRICE SENSITIVE	28/08/20	209.81KB	Share
RCE	Recce Pharmaceuticals Appoints James Graham as CEO	PRICE SENSITIVE	28/08/20	370.03KB	Share
RCE	Positive Oral Data on New RECCE 435 Against H. pylori	PRICE SENSITIVE	04/08/20	757.45KB	Share
RCE	Appendix 4C and Activity Report	PRICE SENSITIVE	31/07/20	476.79KB	Share
RCE	US Researchers to Test RECCE in Expanded SARS-CoV-2 Program	PRICE SENSITIVE	16/07/20	330.61KB	Share
RCE	Pause in Trading	PRICE SENSITIVE	16/07/20	115.78KB	Share
RCE	Reinstatement to Official Quotation	PRICE SENSITIVE	08/07/20	403.6KB	Share
RCE	RCE Selected by CSIRO/PDI for SARS-CoV-2 Antiviral Program	PRICE SENSITIVE	08/07/20	355KB	Share
RCE	Suspension from Official Quotation	PRICE SENSITIVE	08/07/20	332.13KB	Share
RCE	Trading Halt	PRICE SENSITIVE	06/07/20	465.73KB	Share
RCE	Pause in Trading	PRICE SENSITIVE	06/07/20	115.4KB	Share
RCE	Response to ASX Price and Volume Query	PRICE SENSITIVE	27/05/20	306.58KB	Share
RCE	Positive Data on RECCE 327 Against Neisseria gonorrhoeae	PRICE SENSITIVE	04/05/20	452.72KB	Share
RCE	Appendix 4C and Activity Report	PRICE SENSITIVE	29/04/20	400.44KB	Share
RCE	Further Positive Data on RECCE 327 Against MRSA Superbug	PRICE SENSITIVE	23/04/20	875.14KB	Share
RCE	Positive Data on RECCE 327 Against Influenza A	PRICE SENSITIVE	20/04/20	573.09KB	Share
RCE	Trading Halt	PRICE SENSITIVE	16/04/20	272.42KB	Share

RCE Pause in Trading
07/12/22	PRICE SENSITIVE	113.49KB	Share
RCE Quarterly Activities/Appendix 4C Cash Flow Report
28/10/22	PRICE SENSITIVE	581.3KB	Share
RCE Anti-Infective Portfolio Update and Webinar details
19/10/22	PRICE SENSITIVE	3.36MB	Share
RCE Pause in Trading
19/10/22	PRICE SENSITIVE	115.99KB	Share
RCE R327 COVID Study Update
18/10/22	PRICE SENSITIVE	398.4KB	Share
RCE Pause in trading
18/10/22	PRICE SENSITIVE	115.68KB	Share
RCE Expansion and Acceleration of Clinical Programs
27/09/22	PRICE SENSITIVE	308.99KB	Share
RCE Appendix 4E
31/08/22	PRICE SENSITIVE	244.24KB	Share
RCE Phase I Clinical Trial of R327 I.V. - 6000mg Complete
22/08/22	PRICE SENSITIVE	313.84KB	Share
RCE Quarterly Activities/Appendix 4C Cash Flow Report
01/08/22	PRICE SENSITIVE	944.67KB	Share
RCE Corporate Presentation - Aussie Equities Day 2022
28/07/22	PRICE SENSITIVE	2.22MB	Share
RCE Phase I Positive Safety Data - 4000mg Complete
21/06/22	PRICE SENSITIVE	241.36KB	Share
RCE Phase I Clinical Trial R327 Advances to 4000mg
20/05/22	PRICE SENSITIVE	241.06KB	Share
RCE Corporate Presentation - Biotech Investor Lunch
16/05/22	PRICE SENSITIVE	2.48MB	Share
RCE Quarterly Activities/Appendix 4C Cash Flow Report
02/05/22	PRICE SENSITIVE	436.79KB	Share
RCE Phase I Clinical Trial R327 Advances to High Dose Cohort
12/04/22	PRICE SENSITIVE	408.22KB	Share
RCE Anti-Viral Patent Granted in Hong Kong
11/04/22	PRICE SENSITIVE	225.31KB	Share
RCE Positive safety data from 4th Cohort -Phase I Clinical Trial
30/03/22	PRICE SENSITIVE	247.62KB	Share
RCE $3.08m R&D Rebate Received
28/03/22	PRICE SENSITIVE	238.52KB	Share
RCE Safety Committee Clears PhI R327 Dose Increase
07/03/22	PRICE SENSITIVE	265.52KB	Share
RCE S&P DJI Announces March 2022 Quarterly Rebalance
04/03/22	PRICE SENSITIVE	175.5KB	Share
RCE Appendix 4D and Interim Financial Report
28/02/22	PRICE SENSITIVE	265.76KB	Share
RCE Positive Safety Continues in 3rd Cohort PhI Clinical Trial
21/02/22	PRICE SENSITIVE	266.79KB	Share
RCE Positive Safety Data from Third Cohort of PI Clinical Trial
08/02/22	PRICE SENSITIVE	247.91KB	Share
RCE Quarterly Activities/Appendix 4C Cash Flow Report
31/01/22	PRICE SENSITIVE	441.2KB	Share
RCE Positive Safety Data from Second Cohort of PI Clinical Trial
18/01/22	PRICE SENSITIVE	267.69KB	Share
RCE Positive Safety Data from Phase 1 Clinical Trial
07/01/22	PRICE SENSITIVE	316.58KB	Share
RCE Patients to be Dosed in Ph 1 IV Clinical Trial of R327
15/12/21	PRICE SENSITIVE	246.15KB	Share
RCE Update on Phase I/II Clinical Trial for Burn Wound Infection
07/12/21	PRICE SENSITIVE	273.37KB	Share
RCE Opening R&D Address at World AMR Congress
08/11/21	PRICE SENSITIVE	6.74MB	Share
RCE Appendix 4C and Activity Report
29/10/21	PRICE SENSITIVE	413.29KB	Share
RCE Ethics Approval to Start Phase 1 Intravenous Clinical Trial
25/10/21	PRICE SENSITIVE	247.07KB	Share
RCE Reinstatement to Official Quotation
12/10/21	PRICE SENSITIVE	85.72KB	Share
RCE Court Orders Granted
12/10/21	PRICE SENSITIVE	404.72KB	Share
RCE Suspension from Official Quotation
12/10/21	PRICE SENSITIVE	240.35KB	Share
RCE Trading halt
08/10/21	PRICE SENSITIVE	696.71KB	Share
RCE Pause in Trading
08/10/21	PRICE SENSITIVE	116.55KB	Share
RCE R327 Phase I Clinical Trial Registered on ANZCTR
30/09/21	PRICE SENSITIVE	288.3KB	Share
RCE Appendix 4E
31/08/21	PRICE SENSITIVE	261.73KB	Share
RCE Recce Receives Further Innovation Connections Grant
11/08/21	PRICE SENSITIVE	225.61KB	Share
RCE Appendix 4C and Activity Report
30/07/21	PRICE SENSITIVE	433.45KB	Share
RCE Anti-Viral Patent Granted in USA for RECCE Anti-Infectives
22/07/21	PRICE SENSITIVE	270.51KB	Share
RCE Anti-Viral Patent Granted in China
20/07/21	PRICE SENSITIVE	270.49KB	Share
RCE Outstanding Efficacy Against Flesh-Eating Bacteria
19/07/21	PRICE SENSITIVE	423.92KB	Share
RCE Multiple Patients Dosed in Topical Phase I/II Clinical Trial
12/07/21	PRICE SENSITIVE	296.93KB	Share
RCE Recce Clinical Pipeline Update
07/06/21	PRICE SENSITIVE	291.67KB	Share
RCE R327 Demonstrates World First Multiple Mechanisms of Action
27/05/21	PRICE SENSITIVE	1.26MB	Share
RCE R327 to Stage 2 of SARS-CoV-2 Antiviral Screening at CSIRO
19/05/21	PRICE SENSITIVE	328.14KB	Share
RCE Positive Data on RECCE 327 Against All Six ESKAPE Pathogens
04/05/21	PRICE SENSITIVE	883.37KB	Share
RCE Appendix 4C and Activity Report
27/04/21	PRICE SENSITIVE	453.68KB	Share
RCE RECCE 327 Registered for Topical Burns Study in Humans
15/04/21	PRICE SENSITIVE	296.62KB	Share
RCE Positive Sinusitis Patient Update - Special Access Scheme
07/04/21	PRICE SENSITIVE	300.36KB	Share
RCE Positive Sinusitis Data Against Infection
01/04/21	PRICE SENSITIVE	618KB	Share
RCE Anti-Viral Patent Granted in EU for RECCE Anti-Infectives
30/03/21	PRICE SENSITIVE	228.62KB	Share
RCE S&P DJI Announces March 2021 Quarterly Rebalance
12/03/21	PRICE SENSITIVE	183.24KB	Share
RCE Recce Pharmaceuticals Dual Lists on Frankfurt Stock Exchange
08/03/21	PRICE SENSITIVE	329.63KB	Share
RCE Appendix 4D and Half Yearly Report
25/02/21	PRICE SENSITIVE	451.22KB	Share
RCE Recce Applies for Dual Listing on Frankfurt Stock Exchange
24/02/21	PRICE SENSITIVE	325.24KB	Share
RCE Fiona Stanley Hospital Phase I/II Clinical Trial Agreement
16/02/21	PRICE SENSITIVE	413.46KB	Share
RCE Further Encouraging COVID Results at Doherty
12/02/21	PRICE SENSITIVE	409.16KB	Share
RCE R&D Incentive Rebate Received
03/02/21	PRICE SENSITIVE	324.6KB	Share
RCE Appendix 4C and Activity Report
28/01/21	PRICE SENSITIVE	531.85KB	Share
RCE Positive Intranasal Animal Data against SARS-CoV-2 in Study
23/12/20	PRICE SENSITIVE	542.82KB	Share
RCE RCE Awarded AusIndustry Advanced Overseas Anti-Viral Finding
08/12/20	PRICE SENSITIVE	370.39KB	Share
RCE Recce Awarded AusIndustry Advanced Overseas (R&D) Finding
26/11/20	PRICE SENSITIVE	331.4KB	Share
RCE Anti-Viral Patent Granted in Japan for RECCE Anti-Infectives
23/11/20	PRICE SENSITIVE	297.82KB	Share
RCE Reinstatement to Official Quotation
10/11/20	PRICE SENSITIVE	400.35KB	Share
RCE Encouraging Results Against SARS-CoV-2 Virus
10/11/20	PRICE SENSITIVE	454.28KB	Share
RCE Suspension from Official Quotation
05/11/20	PRICE SENSITIVE	422.52KB	Share
RCE Trading Halt
03/11/20	PRICE SENSITIVE	465.12KB	Share
RCE Appendix 4C and Activity Report
21/10/20	PRICE SENSITIVE	797.75KB	Share
RCE HREC Approval to Start Phase I/II Burns Wound Study
16/10/20	PRICE SENSITIVE	331.16KB	Share
RCE Trading Halt
14/10/20	PRICE SENSITIVE	465.67KB	Share
RCE Pause in trading
14/10/20	PRICE SENSITIVE	116.3KB	Share
RCE R&D Incentive Rebate Received
05/10/20	PRICE SENSITIVE	316.17KB	Share
RCE Murdoch Children's Research Institute, R435 Against H.Pylori
30/09/20	PRICE SENSITIVE	377.28KB	Share
RCE Recce Completes Capital Raising of $27.95m
23/09/20	PRICE SENSITIVE	350.89KB	Share
RCE Trading Halt
21/09/20	PRICE SENSITIVE	507.12KB	Share
RCE R327 Phase I Study - Australia's CMAX Clinical Facility
10/09/20	PRICE SENSITIVE	377.7KB	Share
RCE Positive & Concentration-Dependent Efficacy Against COVID-19
08/09/20	PRICE SENSITIVE	621.04KB	Share
RCE Trading Halt
07/09/20	PRICE SENSITIVE	649.24KB	Share
RCE Pause in Trading
07/09/20	PRICE SENSITIVE	116.3KB	Share
RCE Recce Pharmaceuticals Receives Innovation Connections Grant
01/09/20	PRICE SENSITIVE	309.07KB	Share
RCE Appendix 4E
28/08/20	PRICE SENSITIVE	209.81KB	Share
RCE Recce Pharmaceuticals Appoints James Graham as CEO
28/08/20	PRICE SENSITIVE	370.03KB	Share
RCE Positive Oral Data on New RECCE 435 Against H. pylori
04/08/20	PRICE SENSITIVE	757.45KB	Share
RCE Appendix 4C and Activity Report
31/07/20	PRICE SENSITIVE	476.79KB	Share
RCE US Researchers to Test RECCE in Expanded SARS-CoV-2 Program
16/07/20	PRICE SENSITIVE	330.61KB	Share
RCE Pause in Trading
16/07/20	PRICE SENSITIVE	115.78KB	Share
RCE Reinstatement to Official Quotation
08/07/20	PRICE SENSITIVE	403.6KB	Share
RCE RCE Selected by CSIRO/PDI for SARS-CoV-2 Antiviral Program
08/07/20	PRICE SENSITIVE	355KB	Share
RCE Suspension from Official Quotation
08/07/20	PRICE SENSITIVE	332.13KB	Share
RCE Trading Halt
06/07/20	PRICE SENSITIVE	465.73KB	Share
RCE Pause in Trading
06/07/20	PRICE SENSITIVE	115.4KB	Share
RCE Response to ASX Price and Volume Query
27/05/20	PRICE SENSITIVE	306.58KB	Share
RCE Positive Data on RECCE 327 Against Neisseria gonorrhoeae
04/05/20	PRICE SENSITIVE	452.72KB	Share
RCE Appendix 4C and Activity Report
29/04/20	PRICE SENSITIVE	400.44KB	Share
RCE Further Positive Data on RECCE 327 Against MRSA Superbug
23/04/20	PRICE SENSITIVE	875.14KB	Share
RCE Positive Data on RECCE 327 Against Influenza A
20/04/20	PRICE SENSITIVE	573.09KB	Share
RCE Trading Halt
16/04/20	PRICE SENSITIVE	272.42KB	Share

REFRESH

First 2

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 37.5¢		Change 0.000(0.00%)		Mkt cap ! $108.4M

Open	High	Low	Value	Volume
38.0¢	39.0¢	36.5¢	$39.00K	102.4K

Buyers (Bids)

No.	Vol.	Price($)
1	9999	37.5¢

Sellers (Offers)

Price($)	Vol.	No.
39.0¢	2108	1

View Market Depth

No.	Vol.	Price($)
1	9999	0.375
1	60531	0.365
5	85889	0.360
2	85000	0.355
4	88019	0.350

Price($)	Vol.	No.
0.390	2108	1
0.400	23104	2
0.410	25471	1
0.440	18669	3
0.450	35043	4

Last trade - 16.10pm 08/08/2025 (20 minute delay)

RCE (ASX) Chart

RECCE PHARMACEUTICALS LTD - Announcements

Corporate Spotlight

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories